［1］RANJAN A, RAMACHANDRAN S,GUPTA N,et al.Role of phytochemicals in cancer prevention ［J］.Int J Mol Sci,2019,20(20):4981.
［2］PEI S,MINHAJUDDIN M,CALLAHAN KP,et al.Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells ［J］.J Biol Chem,2013,288(47):33542-33558.
［3］TRIPATHI SK,BISWAL BK.PIPERLONGUMINE,a potent anticancer phytotherapeutic:Perspectives on contemporary status and future possibilities as an anticancer agent ［J］.Pharmacol Res,2020,156:104772.
［4］RAJ L,IDE T,GURKAR AU,et al.Retraction note:selective killing of cancer cells by a small molecule targeting the stress response to ROS ［J］.Nature,2011,475(7355):231-234.
［5］HAYESJD,DINKOVA-KOSTOVA AT,TEW KD.Oxidative stress in cancer ［J］.Cancer Cell,2020,38(2):167-197.
［6］SENA LA,CHANDEL NS.Physiological roles of mitochondrial reactive oxygen species ［J］.Mol Cell,2012,48(2):158-167.
［7］TRACHOOTHAM D,ALEXANDRE J,HUANG P.Targeting cancer cells by ROS-mediated mechanisms:a radical therapeutic approach［J］.Nat Rev Drug Discov,2009,8(7):579-591.
［8］WONDRAKGT.Redox-directed cancer therapeutics: molecular mechanisms and opportunities ［J］.Antioxid Redox Signal,2009,11(12):3013-3069.
［9］ZOU P,XIA Y,JI J,et al.Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer ［J］.Cancer Lett,2016,375(1):114-126.
［10］ZHANG Q,CHEN W,LYU X,et al.Piperlongumine,a novel TrxR1 inhibitor, induces apoptosis in hepatocellular carcinoma cells by ROS-mediated ER stress［J］.Front Pharmacol,2019,10:1180.
［11］JIN HO,LEE YH,PARK JA,et al.Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells ［J］.J Cancer Res Clin Oncol,2014,140(12):2039-2046.
［12］ZHOU J, HUANG Z,NI X,et al.Piperlongumine induces apoptosis and G2/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway ［J］.Toxicol In Vitro,2020,65:104775.
［13］THONGSOM S,SUGINTA W,LEE KJ,et al.Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway ［J］.Apoptosis,2017,22(11):1473-1484.
［14］ALLAMAN-PILLET N,SCHORDERET DF.Piperlongumine promotes death of retinoblastoma cancer cells ［J］.Oncotarget,2021,12(9):907-916.
［15］DUAN Z,SU ZH,FANG DW,et al.Research progress in the function of C/EBP homologous protein ［J］.Journal of Molecular Diagnostics and Therapy,2021,13(1):165-168.
［16］DAVIS RJ.Signal transduction by the JNK group of MAP kinases ［J］.Cell,2000,103(2):239-252.
［17］HIBI M, LIN A,SMEAL T,et al.Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain ［J］.Genes Dev,2007,(11):2135-2148.
［18］SHIM HY,PARK JH,PAIK HD,et al.Acacetin-induced apoptosis of human breast cancer MCF-7 cells involves caspase cascade,mitochondria-mediated death signaling and SAPK/JNK1/2-c-Jun activation ［J］.Mol Cells,2007,24(1):95-104.
［19］LIU LJ,TANG SS.Research progress of ROS mediated JNK signaling pathway ［J］.Progress in Modern Biomedicine,2010,10(7):1378-1380.
［20］LIU QR,LIU JM,CHEN Y,et al.Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways ［J］.Oxid Med Cell Longev,2014,2014:653732.
［21］XIONG XX,LIU JM,QIU XY,et al.Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways ［J］.Acta Pharmacol Sin,2015,36(3):362-374.
［22］KUMAR S, AGNIHOTRI N. Piperlongumine targets NF-κB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer［J］.Mol Cell Biochem,2021,476(4):1765-1781.
［23］BORKIEWICZL,KALAFUT J,DUDZIAK K,et al.Decoding LncRNAs ［J］.Cancers (Basel),2021,13(11):2643.
［24］WANG KC,CHANG HY.Molecular mechanisms of long noncoding RNAs ［J］.Mol Cell,2011,43(6):904-914.
［25］KARKI K,HEDRICK E,KASIAPPAN R,et al.Piperlongumine induces reactive oxygen species (ROS)-dependent downregulation of specificity protein transcription factors ［J］.Cancer Prev Res,2017,10(8):467-477.
［26］LU X, XU C,XU Z,et al.Piperlongumine inhibits the growth of non-small cell lung cancer cells via the miR-34b-3p/TGFBR1 pathway ［J］.BMC Complement Med Ther,2021,21(1):15.
［27］DELANEY LM,FARIAS N,GHASSEMI RAD J,et al.The natural alkaloid piperlongumine inhibits metastatic activity and epithelial-to-mesenchymal transition of triple-negative mammary carcinoma cells ［J］.Nutr Cancer,2021,73(11-12):2397-2410.
［28］HU Y, LUO X,ZHOU J,et al.Piperlongumine inhibits the progression of osteosarcoma by downregulating the SOCS3/JAK2/STAT3 pathway via miR-30d-5p ［J］.Life Sci,2021,277:119501.
［29］GUO S,XING D,LYU B.Research progress of apoptosis,programmed cell necrosis and cell scorch ［J］.Journal of Chinese Practical Diagnosis and Therapy,2021,35(3):321-324.
［30］SHI J,GAO W,SHAO F.Pyroptosis:gasdermin-mediated programmed necrotic cell death ［J］.Trends Biochem Sci,2017,42(4):245-254.
［31］LI Q,CHEN L,DONG Z,et al.Piperlongumine analogue L50377 induces pyroptosis via ROS mediated NF-κB suppression in non-small-cell lung cancer ［J］.Chem Biol Interact,2019,313:108820.
［32］HUA JS,WANG SJ,LIU HF.Piperlongumine induces pyroptosis of gastric cancer cells by activating p38/Caspase-3/GSMDME pathway ［J］.Jinagsu Medical Journal,2022,48(03):217-221.
［33］XU R,YANG J,QIAN Y,et al.Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF ［J］.Nanoscale Horiz,2021,6(4):348-356.
［34］CHEN X,KANG R,KROEMER G,et al.Broadening horizons:the role of ferroptosis in cancer ［J］.Nat Rev Clin Oncol,2021,18(5):280-296.
［35］SU Y,ZHAO B,ZHOU L,et al.Ferroptosis,a novel pharmacological mechanism of anti-cancer drugs ［J］.Cancer Lett,2020,483:127-136.
［36］YAMAGUCHI Y,KASUKABE T,KUMAKURA S.Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis ［J］.Int J Oncol,2018,52(3):1011-1022.
［37］YANG Y,SUN S,XU W,et al.Piperlongumine inhibits thioredoxin reductase 1 by targeting selenocysteine residues and sensitizes cancer cells to erastin ［J］.Antioxidants (Basel),2022,11(4):710.
［38］KOMATSU M,WAGURI S,CHIBA T,et al.Loss of autophagy in the central nervous system causes neurodegeneration in mice ［J］.Nature,2006,441(7095):880-884.
［39］XU Z,HAN X,OU D,et al.Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy ［J］.Appl Microbiol Biotechnol,2020,104(2):575-587.
［40］HERAS-SANDOVAL D,PREZ-ROJAS JM,HERN NDEZ-DAMIN J,et al.The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration ［J］.Cell Signal,2014,26(12):2694-2701.
［41］WANG H,WANG Y,GAO H,et al.Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways ［J］.Oncol Lett,2018,15(2):1423-1428.
［42］KUMAR S,AGNIHOTRI N.Piperlongumine,a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer ［J］.Biomed Pharmacother,2019,109:1462-1477.
［43］WANG F,MAO Y,YOU Q,et al.Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway ［J］.Int J Immunopathol Pharmacol,2015,28(3):362-373.
［44］邹向阳,李连宏.细胞周期调控与肿瘤［J］.国际遗传学杂志,2006,29(1):70-73.
ZOU XY,LI LH.Cell cycle control and tumor ［J］.International Journal of Genetics Int J Genet Jun,2006,29(1):70-73.
［45］KONG EH,KIM YJ,CHO HJ,et al.Piplartine induces caspase mediated apoptosis in PC-3 human prostate cancer cells ［J］.Oncol Rep,2008,20:785-792.
［46］WANG H,JIANG H,CORBET C,et al.Piperlongumine increases sensitivity of colorectal cancer cells to radiation:involvement of ROS production via dual inhibition of glutathione and thioredoxin systems ［J］.Cancer Lett,2019,450:42-52.
［47］SONG X,GAO T,LEI Q,et al.Piperlongumine induces apoptosis in human melanoma cells via reactive oxygen species mediated mitochondria disruption［J］.Nutr Cancer,2018,70(3):502-511.
［48］SHRIVASTAVA S,KULKARNI P,THUMMURI D,et al.Piperlongumine,an alkaloid causes inhibition of PI3K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells ［J］.Apoptosis,2014,19(7),1148-1164.
［49］DIEPENBRUCK M,CHRISTOFORI G.Epithelial-mesenchymal transition (EMT) and metastasis:yes,no,maybe ［J］.Curr Opin Cell Biol,2016,43:7-13.
［50］LAMOUILLE S,XU J,DERYNCK R.Molecular mechanisms of epithelial-mesenchymal transition［J］.Nat Rev Mol Cell Biol,2014,15(3):178-196.
［51］CHILVERY S,BANSOD S,SAIFI MA,et al.Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways ［J］.Int Immunopharmacol,2020,88:106909.
［52］GARINET S,DIDELOT A,DENIZE T,et al.Clinical assessment of the miR-34,miR-200,ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC ［J］.Br J Cancer,2021,125(11):1544-1551.
［53］TIAN Y,PAN Q,SHANG Y,et al.MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2):impact on the epithelial-mesenchymal transition in colon cancer cells ［J］.J Biol Chem,2014,289(52):36101-36115.
［54］LIU D,QIU XY,WU X,et al.Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization ［J］.Biochem Biophys Res Commun,2017,494(1-2):165-172.
［55］ZHANG J,LI X,HAN X,et al.Targeting the thioredoxin system for cancer therapy ［J］.Trends Pharmacol Sci,2017,38(9):794-808.
［56］YAO JX,YAO ZF,LI ZF,et al.Radio-sensitization by piper longumine of human breast adenoma MDA-MB-231 cells in vitro ［J］.Asian Pac J Cancer Prev,2014,15(7):3211-3217.
［57］KANG Q,YAN S.Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells ［J］.Exp Ther Med,2015,9(4):1345-1350.
［58］PISKA K,KOCZURKIEWICZ P,WNUK D,et al.Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition ［J］.Chem Biol Interact,2019,300:40-48.
［59］ROH JL,KIM EH,PARK JY,et al.Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer ［J］.Oncotarget,2014,5(19):9227-9238.
［60］TAN LJ,LIU YQ,YAN J,et al.Advances in synthesis,antitumor mechanism and structural modification of piperlongumine ［J］.China Pharmacy,2021,32(4):508-512.
［61］ZHU CP.The key problem of tumor treatment based on ros - discussion on ros and its dose effect［D］.Hangzhou:Zhejiang University,2015.